Bart Fevery

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Eric Lawitz, Mark Sulkowski, Reem Ghalib et al. · The Lancet · 2014 · 814 citations

Hepatology, Hepatitis C, Viral Hepatitis +9

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

Paul Y. Kwo, Norman Gitlin, Ronald Nahass et al. · Hepatology · 2016 · 189 citations · Full text

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

Eric Lawitz, Gary Matusow, Edwin DeJesus et al. · Hepatology · 2015 · 180 citations · Full text

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies

Oliver Lenz, Thierry Verbinnen, Bart Fevery et al. · Journal of Hepatology · 2014 · 131 citations · Full text

Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202)

Oliver Lenz, Leen Vijgen, Jan Martin Berke et al. · Journal of Hepatology · 2012 · 87 citations

Viral Hepatitis, Hcv Genotype 2–6, Antiviral Therapy +8